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Chronic or excess glucocorticoid exposure causes lipid disor-
ders such as hypertriglyceridemia and hepatic steatosis. Angptl4
(angiopoietin-like 4), a primary target gene of the glucocorticoid
receptor in hepatocytes and adipocytes, is required for hypertrig-
lyceridemia and hepatic steatosis induced by the synthetic gluco-
corticoid dexamethasone. Angptl4 has also been shown to be
required for dexamethasone-induced hepatic ceramide produc-
tion.Here,we furtherexamined the roleof ceramide-mediated sig-
naling in hepatic dyslipidemia caused by chronic glucocorticoid
exposure. Using a stable isotope-labeling technique, we found that
dexamethasone treatment induced the rate of hepatic de novo
lipogenesis and triglyceride synthesis. These dexamethasone
responses were compromised in Angptl4-null mice (Angptl4/).
Treating mice with myriocin, an inhibitor of the rate-controlling
enzyme ofde novo ceramide synthesis, serine palmitoyltransferase
long-chain base subunit 1 (SPTLC1)/SPTLC2, decreased dexam-
ethasone-induced plasma and liver triglyceride levels in WT but
not Angptl4/ mice. We noted similar results in mice infected
with adeno-associated virus–expressing small hairpin RNAs tar-
getingSptlc2.Proteinphosphatase2phosphataseactivator (PP2A)
andproteinkinaseC (PKC) are twoknowndownstreameffectors
of ceramides.We foundhere thatmice treatedwith an inhibitor of
PKC, 2-acetyl-1,3-cyclopentanedione (ACPD),had lower levelsof
dexamethasone-induced triglyceride accumulation in plasma and
liver. However, small hairpin RNA–mediated targeting of the cat-
alytic PP2A subunit (Ppp2ca) had no effect on dexamethasone
responses on plasma and liver triglyceride levels. Overall, our
results indicate that chronic dexamethasone treatment induces an
ANGPTL4–ceramide–PKC axis that activates hepatic de novo
lipogenesis and triglyceride synthesis, resulting in lipid disorders.
Chronic exposure to glucocorticoids has long been associated
with the development of lipid disorders including dyslipidemia
and hepatic steatosis (1–3). In contrast, reducing glucocorticoid
levels, such as inhibiting 11-hydroxysteroid dehydrogenase type
1, an enzyme converting inactive glucocorticoids to active hor-
mones, reduces plasma and liver TG levels in animal models of
metabolic syndrome (4–7) and nonalcoholic fatty liver disease
patients (8). In fact, an inhibitor for 11-hydroxysteroid dehydro-
genase type 1 is currently under clinical trial phase 1b, which
showed a modest but significant improvement of nonalcoholic
fatty liver disease (NAFLD)3 (8). Antagonists for the glucocorti-
coid receptor (GR) also improve plasma lipid profiles (9, 10).
Despite these long-establishedobservations, themechanismsgov-
erning these glucocorticoid effects are not entirely clear. Chronic
glucocorticoid exposure has been shown to induce de novo lipo-
genesis (DNL) and triglyceride (TG) synthesis in liver (11, 12).
However, treating hepatocytes with glucocorticoids alone does
not always promote lipogenesis (13, 14). Thus, the induction of
hepatic DNL and TG synthesis by chronic glucocorticoid expo-
suremayrequireadditional signalsor theeffectsof glucocorticoids
on other tissues.
It has been proposed that the excess lipolysis induced by GC
in white adipose tissue plays a role in the development of dys-
lipidemia and fatty liver (15, 16). This proposed mechanism is
in agreement with previous observations showing that gluco-
corticoid-induced hepatic steatosis and hypertriglyceridemia
are dependent on the presence ofAngptl4 (angiopoietin-like 4),
a GR primary target gene (17). Angptl4 encodes a secreted pro-
tein that can promote intracellular lipolysis in adipocytes (18).
It has been shown that glucocorticoid-stimulated lipolysis in
white adipose tissue is attenuated inmice lackingAngptl4 (Ang-
ptl4/) and purified ANGPTL4 protein directly induces lipol-
ysis in mouse primary adipocytes (18). Thus, it is conceivable
that Angptl4mediates glucocorticoid stimulation of lipolysis in
white adipose tissue, which mobilizes fatty acids to the liver for
TG synthesis and storage. Notably, Angptl4 has also been
shown to be required for glucocorticoids to stimulate hepatic
ceramide production, which activates protein phosphatase 2A
and protein kinase C (PKC) to suppress insulin signaling in
liver (19). Because hepatic ceramide levels have been posi-
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tively associated with NAFLD (20–22), we hypothesize that
glucocorticoid-induced Angptl4-dependent hepatic produc-
tion or ceramides are involved in the development of hepatic
steatosis and hypertriglyceridemia. In this study, we exam-
ined this model and also identified the downstream effectors
of ceramide-mediated signaling that mediate glucocorticoid
response on hepatic TG homeostasis.
Results
Chronic dexamethasone exposure–induced hepatic DNL and
TG synthesis was attenuated in Angptl4/mice
MaleWT andAngptl4/mice were treated with or without
dexamethasone (a synthetic glucocorticoid) for 7 days. At the
endof the treatment, blood and liverwere collected, andplasma
and liver TG levels were measured. Dexamethasone treatment
significantly elevated plasma and liver TG levels in WT mice
(Fig. 1,A andB). These dexamethasone effects were suppressed
inAngptl4/mice (Fig. 1,A and B). To examine whether dex-
amethasone treatment stimulates hepatic DNL andTG synthe-
sis and the role of Angptl4 in these processes, we applied a
stable isotope labeling technique. In the liver of PBS-treated
WT mice, the absolute rate of DNL (mg palmitate synthesized
over a 24-h labeling period) was 0.08 mg palmitate/day/mouse
(Fig. 1C). Dexamethasone treatment for 7 days resulted in a
40-fold induction in the absolute DNL rate (3.2 mg palmitate/
day; Fig. 1C). In contrast, the absolute rate of DNL in the liver of
untreated Angptl4/ mice was 0.09 mg palmitate/day (Fig.
1C). Dexamethasone treatment increased the rate of DNL 2.4-
fold (to 0.22 mg palmitate/day; Fig. 1C). This induction was
markedly lower than the dexamethasone response in liver of
WTmice (p 0.05). These results demonstrate that Angptl4 is
involved chronic dexamethasone exposure–stimulated hepatic
DNL.
Dexamethasone treatment also resulted in 6-fold induction
of the absolute rate of TG synthesis in the liver ofWTmice (Fig.
1D). The absolute TG synthesis rate in liver of untreated Ang-
ptl4/ mice was not statistically significantly different from
untreatedWTmice (Fig. 1D). Dex treatment did not elevate the
absolute hepatic TG synthesis rate in Angptl4/ mice (Fig.
1D). These results demonstrate that without Angptl4, the abil-
ity of Dex to augment TG synthesis in the liver was diminished.
The ability of dexamethasone to induce lipogenic genes in
liver was attenuatedwithout Angptl4
We analyzed the expression of genes involved in DNL and
TG synthesis in the liver of WT and Angptl4/ mice treated
with or without dexamethasone. We found that the expression
of genes encoding enzymes in DNL and TG synthesis, such as
Fasn, Acaca, Acacb, Dgat2, Gpat1, and Lpin1, were increased
by dexamethasone in WT mice liver (Fig. 2A). In Angptl4/
mice, the ability of Dex to activate these genes was significantly
reduced (Fig. 2A). Interestingly, dexamethasone treatment sig-
nificantly reduced the expression of Srebp1c, a transcription
factor that activates the transcription of many lipogenic genes
(23, 24), in WT mice liver (Fig. 2A). In Angptl4/ mice, the
reduction of Srebp1c expression by dexamethasone was even
more profound (Fig. 2A). In contrast, the expression of
Chrebp, another transcription factor that augments lipogenic
gene transcription (25), was markedly enhanced inWT but not
Angptl4/ mice liver (Fig. 2A). The expression of Chrebp, a
longer isoform ofChrebp (24, 26), however, was not affected by
dexamethasone (Fig. 2A). However, the expression of Chrebp
was still reduced in Angptl4/ mice liver (Fig. 2A). The fact
that Srebp1c expression was reduced by chronic dexametha-
sone exposure raised a question regardingwhether Srebp1cwas
activated to promote lipogenic and TG synthetic gene tran-
scription. Interestingly, protein levels of the mature and the
immature forms of Srebp1c in the whole cell extracts and the
mature form of Srebp1c in the nuclear extracts isolated from
control and dexamethasone-treated liver were similar (Fig. 2B).
These results demonstrated that despite the reduction of
Srebp1cmRNA by dexamethasone treatment, Srebp1c protein
levels were not significantly decreased by dexamethasone treat-
ment for the time period conducted in our experiments. We
performed ChIP experiments to further examine the recruit-
ment of Srebp1c to its binding site in the Fasn gene. We found
that Srebp1c was recruited to the Fasn gene promoter without
dexamethasone treatment, which likely provides the basal lipo-
genic action (Fig. 2C). Dexamethasone treatment further
enhanced the Srebp1c recruitment to the Fasn gene promoter
(Fig. 2C). These results are in agreement with the increased
lipogenic rate in the livers of dexamethasone-treated mice.
Figure 1. Angptl4 is required for chronic dexamethasone treatment-ac-
tivated DNL and TG synthesis.WT and Angptl4/mice were treated with
or without dexamethasone (2.5 mg/kg body weight) in drinking water for 7
days. At day 6, the mice were given a priming intraperitoneal bolus injection
of 99.9% labeled with heavy water (2H2O) that contains 0.9% (w/v) sodium
chloride to quickly raise the concentration of heavy water in body water to
5%. This 5% 2H2O concentration was maintained by ad libitum administra-
tion of 8% 2H2O drinkingwater throughout the 24-h labeling period. A and B,
at the end of treatment, the levels of TG in plasma (A) and liver (B) were
measured. The error bars represent standard deviation (n 5–7). *, p 0.05.
Moreover, the fatty acids andglycerol-moietiesof TGs isolated from liverwere
analyzed by GC-MS to quantify the mass isotopomer abundances. C and D,
the absolute rate of DNL (C) and TG synthesis (D) were calculated based on 2H
incorporation into TG-palmitate and TG-glycerol and their respective mea-
suredpool sizes in the tissue. The error bars represent standarddeviation (n
4). *, p 0.05.
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A ceramide synthesis inhibitor reduced chronic
dexamethasone exposure–increased plasma and liver TG
levels
We previously showed that chronic dexamethasone expo-
sure increased the accumulation of various species of ceramides
in the liver of WTmice, and these dexamethasone effects were
attenuated in the liver of Angptl4/ mice (19). To examine
whether ceramides are involved in dexamethasone-induced
hepatic steatosis and hypertriglyceridemia, WT and Ang-
ptl4/ mice were treated with dexamethasone, and with or
without myriocin, an inhibitor of serine palmitoyltransferase 1
and 2 (Spt1/2), rate-controlling enzymes in the de novo cer-
amide synthesis pathway (27). Dexamethasone treatment was
for 7 days, whereas myriocin was included in the final 4 days.
Myriocin treatment decreasedTG levels in both the plasma and
the liver of dexamethasone-treated WT mice (Fig. 3, A and B).
The TG levels in liver of dexamethasone-treated Angptl4/
mice were significantly lower than those of dexamethasone-
treatedWTmice (Fig. 3,A andB).However, in dexamethasone-
treated Angptl4/ mice, myriocin did not further reduce the
TG levels in plasma and liver (Fig. 3, A and B). These results
suggest that increased ceramide production plays a key role in
Angptl4 function in dexamethasone-inducedTGaccumulation
in the plasma and the liver.
We next monitored the effect of myriocin on the expression
of lipogenic and TG synthetic genes in the liver of myriocin-
treated WT and Angptl4/ mice. We found that the expres-
sion of lipogenic genes, such as Fasn, Acaca, and Chrebp, was
reduced in the liver ofmyriocin-treatedWTmice (Fig. 3C). The
expression of Srebp1c,Cd36, andChrebp, although not statis-
tically significant, was also trending lower in myriocin-treated
WT mice (Fig. 3C). Myriocin treatment did not affect the
expression of these genes in Angptl4/ mice. These results
suggest that ceramide production is required for Angptl4’s role
in the induction of lipogenic gene expression by chronic dexa-
methasone exposure. Interestingly, the expression of TG syn-
thetic genes, such asDgat2,Gpat1, and Lpin1,was not affected
by myriocin treatment. We also found that myriocin increased
the expression of Angptl4 in the liver but not epididymal white
adipose tissue of WT mice treated with dexamethasone
(Fig. 3D).
To further confirm that the hepatic ceramide synthetic path-
way is involved in triglyceride accumulation in the plasma and
liver, we infected WT mice with adeno-associated virus (sero-
type 8) expressing scramble (control) small hairpin RNA
(shRNA) or shRNA targeting Sptlc2, which encodes a rate-con-
trolling enzymeofde novo ceramide synthesis. Thesemicewere
called AAV8-shSCR and AAV8-shSptlc2, respectively. We
found that hepatic Sptlc2 expression was significantly lower in
the liver of AAV8-shSptlc2mice (Fig. 3E).Moreover, upon dex-
amethasone treatment, plasma and liver triglyceride levels were
also significantly lower in AAV8-shSptlc2 mice than those of
AAV8-shSCRmice (Fig. 3, F andG. These results are similar to
those of the myriocin treatment experiments above (Fig. 3, A
and B).
PKC but not PP2A is required for chronic dexamethasone
exposure–induced plasma and liver TG accumulation
PKC and PP2A are two known downstream effectors of cer-
amides. To examine whether PP2A is involved in glucose intol-
erance induced by glucocorticoids, WT mice were infected
with adenovirus expressing scrambled shRNA or shRNA tar-
geting Ppp2ca, which encodes the PP2A catalytic subunit.
These mice were called Ad-shSCR and Ad-shPpp2ca, respec-
tively. Western blots validated a significant reduction in the
protein abundance of Ppp2ca by shRNA in mouse liver (Fig.
4A). However, we did not observe significant differences in
plasma and liver TG levels between dexamethasone-treated
Ad-shSCR and Ad-shPpp2camice (Fig. 4, B and C).
To test the role of PKC in glucocorticoid-induced hepatic
hypertriglyceridemia, WT and Angptl4/ mice were injected
with or without 2-acetyl-1,3-cyclopentanedione (ACPD), an
inhibitor of atypical PKC, PKC, and PKC (28, 29) for the final
4 days of the 7-day dexamethasone course. Western blots
showed that ACPD treatment reduced the levels of phosphor-
ylated PKC in liver (Fig. 5A), which indicates reduced PKC
activity. We found that ACPD treatment reduced both plasma
and liver TG accumulation in WT but not Angptl4/ mice
(Fig. 5, B and C). Based on these results, PKC but not PP2A is
involved in chronic dexamethasone-induced hepatic steatosis
and hypertriglyceridemia.
To confirm whether PKC is downstream of ceramides, we
performedWestern blots tomonitor phosphorylated PKC lev-
els in the liver of dexamethasone-treated WT and Angptl4/
mice thatwere treatedwith orwithoutmyriocin.We found that
the relative ratio of phosphorylated PKC and total phosphor-
ylated PKC was reduced in liver of WT mice (Fig. 5D). These
results confirmed that ceramide production is involved in
chronic dexamethasone treatment-induced PKC activity. We
also found that Angptl4 expression was decreased by ACPD
treatment in epididymal white adipose tissue but not liver of
WT mice (Fig. 5E).
The antagonist of PPAR did not affect chronic
dexamethasone exposure–induced plasma and liver TG
accumulation
PPAR has been previously implicated in the production of
ceramides in various cell types (30–32). Moreover, PPAR has
been shown to be involved in glucocorticoid-induced hepatic
gluconeogenesis and insulin resistance (33). We therefore
examine whether PPAR is involved in dexamethasone
treatment–induced plasma and liver triglyceride accumulation.
Figure2.Chronicdexamethasone treatment-inducedexpressionofgenes involved inhepatic TGhomeostasiswas reduced inAngptl4/mice.A,WT
andAngptl4/micewere treatedwith orwithout dexamethasone (0.84mg/kgbodyweight) in drinkingwater for 7 days. RNA from the liver of thesemicewas
isolated, and real-timePCRwasperformed tomonitor the expressionof genes involved inhepatic TGhomeostasis. The error bars represent S.E. (n7–8). *,p
0.05. B, whole cell andnuclear extractswere prepared fromWTandAngptl4/mice treatedwith andwithout dexamethasone for 7 days. Extractswere proved
for Srebp1c levels thatwere normalized to-actin. The error bars represent standarddeviation (n 3). *,p 0.05.C, mouse Fasnpromoter sequences between
116 and20 relative to the transcription start sitewere amplifiedbyChIPprimers. SRE site is labeled (49). Srebp1cChIPwasperformed in the liver ofWTmice
treated with or without dexamethasone (0.84 mg/kg body weight) in drinking water for 7 days. The error bars represent S.E. (n 5). *, p 0.05.
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WTmice treatedwith dexamethasonewere treatedwith PBS or
a PPAR antagonist GW-6471. GW-6471 treatment improved
glucose tolerance in dexamethasone-treated mice (Fig. 6A).
These results were in agreement with the previous observation
that showed the improvement of dexamethasone-regulated
glucose homeostasis in PPAR knockout mice (33). However,
GW-6471 treatment did not affect the accumulation of plasma
and liver triglyceride levels inmice under dexamethasone treat-
ment (Fig. 6, B and C).
Discussion
Dyslipidemia is one of the major adverse effects caused by
chronic and/or excess glucocorticoid exposure. However, the
mechanisms underlying this alteration aremostly unclear.Here
we showed that dexamethasone treatment for 7 days elevated
hepatic DNL and TG synthesis. Interestingly, previous studies
show that glucocorticoid treatment alone on primary hepato-
cytes or hepatoma cells usually does not promote lipogenesis
and/or TG synthesis (11, 12). This suggests that glucocorticoid
effects on cell types other than hepatocytes are required for the
enhancement of hepatic DNL and TG synthesis. Here we
showed that Angptl4-dependent hepatic ceramide production
is involved in chronic dexamethasone treatment-induced
hepatic steatosis and hypertriglyceridemia (Fig. 7). Angptl4 is a
GR primary target gene encoding a secreted protein that inhib-
its lipoprotein lipase through its N-terminal coiled-coil domain
(34, 35) and promotes intracellular lipolysis in adipocytes via a
C-terminal fibrinogen-like domain (36). Such extrahepatic
functions of Angptl4 perfectly fit into the model, in which tis-
sues other than liver are involved in chronic glucocorticoid
responses on lipid homeostasis. However, it is unclear which
function of Angptl4 mediates the dexamethasone response on
hepatic DNL and TG synthesis. We propose that the lipolytic
activity of Angptl4 is required for promoting the mobilization
of fatty acids fromwhite adipose tissue to the liver for ceramide
production because palmitoyl-CoA is a precursor of de novo
ceramide synthesis. Notably, the role of Angptl4 in glucocorti-
coid-promoted hepatic ceramide production is not limited to
providing substrates for de novo ceramide biosynthesis. The
induction of genes encoding enzymes in the ceramide synthetic
pathway by chronic dexamethasone treatment also requires
Angptl4 (19). Nonetheless, we have not excluded the potential
involvement of the LPL inhibitory activity ofAngptl4 in chronic
glucocorticoid exposure–induced lipid disorders. Future stud-
ies to explore the metabolic source of hepatic ceramides will be
of interest. Animal models that specifically disable either func-
tion of Angptl4 are needed to address this question.
Hepatic ceramide levels have been associated with NAFLD.
However, the exact mechanisms of how ceramide-initiated
Figure 3. Myriocin (MYR) treatment reduced chronic dexamethasone exposure–induced hepatic steatosis and hypertriglyceridemia. WT and Ang-
ptl4/micewere treatedwithdexamethasone (0.84mg/kgbodyweight) in drinkingwater for 7days. Half of themice receiveddaily intraperitoneal injections
of myriocin (0.5 mg/kg body weight) on days 4–7. A and B, at the end of treatment, the levels of TG in plasma (A) and liver (B) were measured. The error bars
represent standarddeviation (n6–8). *,p0.5.C, RNA from the liver of thesemicewas isolated, and the expressionof genes involved in TGhomeostasiswas
monitored by real-time PCR. The error bars represent S.E. (n  7–9). *, p  0.05. D, liver and epididymal white adipose tissue RNA was isolated, and gene
expression forAngptl4wasmeasured. The error bars represent S.E. (n 7–9). *, p 0.05.WTmicewere infectedwith adeno-associated virus (AAV8) expressing
shRNA for scramble or Sptlc2 andwere treatedwith dexamethasone for 2 weeks. E, liver was harvested and analyzed for decreased expression of Sptlc2. F and
G, plasma (F) and liver (G) triglyceride levels were measured. The error bars represent standard deviation (n 3–4). *, p 0.05.
Figure 4. Reducing the expression of Ppp2ca did not affect chronic dexamethasone exposure–induced hepatic steatosis and hypertriglyceridemia.
WTmice were infected with adenovirus expressing scramble shRNA or shRNA targeting Ppp2ca. Two days post-infection, themice were treated with dexam-
ethasone (0.84mg/kg bodyweight) in drinkingwater for 7 days. A, at the end of treatment, liver was isolated, andWestern blottingwas performed to confirm
the reduction of Ppp2ca expression in Ad-shPpp2ca mice. B and C, the intensity of the bands was normalized to Gapdh, and plasma (B) and liver (C) TG were
measured in these mice. The error bars represent standard deviation (n 4). *, p 0.05.
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Figure 5. ACPD treatment reduced chronic dexamethasone exposure–induced hepatic steatosis and hypertriglyceridemia.WT and Angptl4/mice
were treated with dexamethasone (0.84 mg/kg body weight) in drinking water for 7 days. Half of the mice of each group were receiving daily subcutaneous
injection of ACPD (10mg/kg bodyweight, dissolved in PBS) on days 4–7. A, at the end of treatment, liver was isolated, andWestern blottingwas performed to
confirm the reduced levels of phosphorylated PKC. The intensity of the bands were normalized to Gapdh. The relative ratio of phosphorylated PKC to PKC
represents thePKC activity.B andC, the levels of TG inplasma (B) and liver (C)weremeasured fromthesemice. The error bars represent standarddeviation (n
4). *, p 0.05. D, Western blotting was performed to monitor the levels of phosphorylated PKC in the liver of 7-day dexamethasone-treated WT mice that
received daily intraperitoneal injection of PBS or myriocin (MYR) (0.5 mg/kg body weight) in the final 4 days. E, liver and epididymal white adipose tissue RNA
were isolated, and gene expression for Angptl4was measured. The error bars represent standard deviation (n 4). *, p 0.05.
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signaling causes TG accumulation are not entirely clear. Here
we found that among two known effectors downstream of cer-
amides, only PKC, but not PP2A, is involved in chronic dexa-
methasone treatment-induced TG accumulation in liver and
plasma (Fig. 6). These results are intriguing because we previ-
ously showed that GR-Angptl4-ceramide axis also causes insu-
lin resistance, but that both PKC and PP2A were involved in
the process (Fig. 7) (19). Insulin resistance has long been asso-
ciated with the development of dyslipidemia (37–39). The fact
that reducing PP2A activity improves insulin sensitivity with-
out affecting plasma and liver TG homeostasis indicates that
chronic glucocorticoid exposure–induced lipid disorders are,
in certain degrees, independent of insulin resistance. PKC has
been shown to phosphorylate and mobilize the transcriptional
coregulator Baf60c from the cytosol to the nucleus to coactivate
with theDNA-binding transcription factorUSF1/2 to stimulate
transcription of lipogenic genes (40).
Various animal models have been used to study the mecha-
nismof hepatic ceramide-initiated signaling in the regulation of
lipid homeostasis. Liver-specific Cers6 (ceramide synthase 6)
knockout mice have reduced levels of C16:0 ceramides and are
protected from high-fat diet–induced hepatic steatosis (41). In
the liver of these mice, fatty acid oxidation is elevated (41).
Haploinsufficiency forCers2 (ceramide synthase 2), which pref-
erentially makes very-long-chain (C22/C24/C24:1) ceramides,
led to compensatory increases in C16:0 ceramides and con-
ferred susceptibility to diet-induced steatohepatitis. The inac-
tivation of electron transport chain components in liver of these
mice resulted in impaired -oxidation (42). Moreover, mice
overexpressingAcer2 (acid ceramidase 2) in the liver were pro-
tected from high-fat diet–induced hepatic steatosis (29). These
mice have decreased liver levels of C16:0 and C18:0 ceramides,
decreased hepatic fatty acid uptake, and decreased expression
of lipogenic genes (29). In agreementwith our results, this study
also found that PKC is involved in ceramide-initiated lipid
disorders. Overall, these previous reports indicate that the lev-
els of C16:0 ceramides appear to be associated with excess TG
accumulation in liver. Notably, our previous results found that
dexamethasone treatment increased the expression of Cers3,
Figure 6. PPAR antagonist GW-6471may improve glucose tolerance under dexamethasone exposure but has no effect on plasma and liver triglyc-
erides. WT mice were treated with dexamethasone (0.84 mg/kg body weight) in drinking water for 7 days. Half of the mice received daily subcutaneous
injection of GW-6471 (10 mg/kg body weight, dissolved in PBS) on days 4–7. A, after 7 days of dexamethasone treatment, the mice were fasted 16 h, an
intraperitoneal glucose tolerance testwasperformed, and the relative areaunder the curvewas calculated.BandC, themicewere allowed to recover for 2days,
and plasma (B) and liver (C) triglyceride levels were measured. The error bars represent standard deviation (n 4). *, p 0.05.
Figure 7. Model of glucocorticoid-induced hepatic steatosis in an Ang-
ptl4- and ceramide-dependentmanner.Glucocorticoids bind to the gluco-
corticoid receptor, which regulates the expression of primary target genes.
Angptl4 is a glucocorticoid primary target gene that we found to be involved
in hepatic ceramide production and hepatic triglyceride accumulation. PP2a
andPKCare twodownstreameffectorsof ceramides. Inour investigation,we
found that PKC, but not PP2a, was required for glucocorticoid stimulated
hepatic triglyceride accumulation.
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Cers4, Cers5, and Cers6 in the liver. Because Cers5 and Cers6
are responsible for the production of C16:0 ceramides, they are
twomajor candidates thatmediate dexamethasone response on
hepatic lipid metabolism. Future experiments should confirm
this model.
Our results also showed that chronic dexamethasone expo-
sure elevated the expression of hepatic lipogenic and TG syn-
thetic genes, which were reduced inAngptl4/mice. Interest-
ingly, myriocin treatment only reduced the expression of genes
involved inDNLbut did not affect the dexamethasone response
on the expression of TG synthetic genes, such as Dgat2, Lpin1,
and Gpat1. This observation is somewhat in agreement with
the role of PKC in hepatic lipidmetabolism.Overexpression of
PKC in mouse liver strongly increased the expression of lipo-
genic genes, such as Fasn, Acaca, and Srebp1c (40). Dgat2 and
Lpin1 were not activated by hepatic PKC overexpression,
whereas the induction ofGpat1was weak (1.3-fold) (40). Based
on these results, ceramide-initiated signaling mainly mediates
chronic glucocorticoid exposure–induced DNL but not TG
synthesis. This notion will need to be further confirmed.More-
over, these gene expression results also suggest that there is
another pathway downstream of Angptl4 that regulates Dgat2
and Lpin1.
In conclusion, in this report we identify an Angptl4–cer-
amide–PKC signaling axis that mediates chronic glucocorti-
coid exposure–modulated hepatic TGhomeostasis. The exten-
sive dissection of this signaling pathway in future studies should
identify more novel and specific targets for treating NAFLD
and dyslipidemia.
Materials andMethods
Animals
Angptl4/ mice were provided by the laboratories of
Andras Nagy (Samuel Lunenfeld Research Institute, Mount
Sinai Hospital) and Jeff Gordon (Washington University) (43).
Angptl4/ mice were generated on a mixed B6:129 Sv back-
ground. Angptl4/ mice (WT mice) were the littermates of
Angptl4/ mice. Male 7–12-week-old mice were used in this
study. They were co-housed and were fed a diet of 18% protein,
6% fat (Envigo 2918). Themice were housed in ventilated cages
with Sanichip bedding along with a cotton Nestlet and a 4-gm
puck of crinkled paper. Genotyping method was performed as
previously described (43). Tissues were harvested between 10
and 11 a.m. in the morning, and all plasma triglyceride mea-
surements were performed on unfasted blood. All mice
received humane care according the criteria laid out in the
Guide for the Care and Use of Laboratory Animals, and the
Office of Laboratory Animal Care at the University of Califor-
nia, Berkeley approved all the animal experiments (approval no.
AUP-2014-08-6617). Themice were housed on a 12-h light and
dark cycle in a temperature-controlled room of22 °C.
Stable isotope labeling, mass spectrometric analysis, and
calculations
At day 6 of dexamethasone water treatment, the mice were
given a priming intraperitoneal bolus injection of 99.9% heavy
water (2H2O) containing 0.9% (w/v) sodium chloride at 0.035
liter/kg bodyweight to quickly raise the concentration of heavy
water in body water to 5% (Sigma; 151890-250G). This 5%
2H2O concentration was maintained for 24 h by ad libitum
administration of 8% 2H2O in the drinking water that was pre-
pared from a 70% deuterium oxide stock (Sigma; 13428-1kg).
After 24 h, the mice were sacrificed, and the fatty acids and
glycerolmoieties of hepatic triglycerides were isolated from the
liver. GC-MSwas then used tomeasure the enrichment ofmass
isotopomers in the TG-fatty acid and TG-glycerol moieties.
The fractions of newly synthesized TG-palmitate and TG-glyc-
erol over the 24-h labeling period were calculated by mass iso-
topomer distribution analysis, with correction for precursor
pool 2H2O enrichment, as described in detail previously
(44, 45).
Drug administration
Male 7–12-week-old Angptl4/ (WT) and Angptl4/
mice were treated with 2.5 or 0.84 mg/kg of dexamethasone
for 7 days through drinking water. Dexamethasone sodium
phosphate (Sigma; PHR1768) was dissolved in drinking water
(6.5 mg/liter). Dexamethasone sodium phosphate has a molec-
ular weight of 516.4 g/mol, and dexamethasone has amolecular
weight of 392.47 g/mol, so there is 760 mg of dexamethasone
per gram of dexamethasone sodium phosphate powder. We
prepared drinking water that contains 0.00651 g of dexameth-
asone per liter and based on our estimate that a 30-g mouse
drinks3.5 ml of water per day. In the myriocin experiments,
myriocin (Sigma; M11777-5MG) (0.5 mg/kg body weight) was
dissolved in PBS and was injected intraperitoneally to mice on
the last 4 days of dexamethasone treatment. For ACPD (Sigma;
A155) treatment, the mice were injected subcutaneously with
10 mg/kg of ACPD dissolved in PBS for 4 days. There was no
difference in water intake between WT and Angptl4/ mice.
In the GW-6471 experiments, GW-6471 (Tocris, Bristol, UK;
4618) (10 mg/kg body weight) (46) was dissolved in 500 l of
DMSO, which was then diluted in PBS to a final concentration
of 1 mg/ml and was injected intraperiotoneally on the last 4
days of dexamethasone treatment.
Western blotting
The protein concentration of samples was measured using a
BCA protein assay (Thermo Scientific; 23228). Protein (30
g) was mixed with 1 NuPAGE LDS sample buffer (Thermo
Fisher; NP0007) and 1 NuPAGE sample reducing agent
(Thermo Fisher; NP0009) and boiled for 5 min before being
applied to SDS-PAGE. The following are the antibodies we
used in this study: anti-Gapdh (Santa Cruz Biotechnology;
sc-25778), anti–-actin (Thermo Fisher; MA1140), anti-PKC
(Santa Cruz Biotechnology; sc-216), anti-phospho-PKC
(T410; Cell Signaling; 2060S), anti-Ppp2ca (Cell Signaling;
2038S), goat anti-rabbit IRDye 800 (Li-Cor, Lincoln, Nebraska;
926-32211), and anti-Sptlc2 (EMD Millipore, Burlington, MA;
ABS1641). The intensity of the bands was quantified using
ImageJ software (National Institute of Health) and normalized
to Gapdh.
Quantitative real-time PCR
Total RNA was isolated from liver tissues using TRIzol re-
agent (Invitrogen; 15596018). Reverse transcription was per-
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formed as follows: 0.5 g of total RNA, 4 l of 2.5 mM dNTP,
and 2 l of 15 M random primers (New England Biolabs, Ips-
wich, MA, S1254S) were mixed at a volume of 16 l and incu-
bated at 70 °C for 5 min. A 4-l mixture containing 25 units of
Moloney murine leukemia virus reverse transcriptase (New
England Biolabs; M0253S), 10 units of RNasin Plus (Promega;
N261B), and 2 l of 10 Moloney murine leukemia virus
reverse transcriptase reaction buffer (New England Biolabs;
B0253S) were added, and samples were incubated at 42 °C for
1 h and then at 95 °C for 5min. The cDNAwas diluted and used
for real-time quantitative PCR (qPCR using the Power Eva
qPCRSuperMix kit (Biochain, Newark, CA; K5057400), follow-
ing the manufacturer’s protocol. qPCR was performed on the
StepOne PCR system (Applied Biosystems) and analyzed with
the Ct method, as supplied by the manufacturer (Applied
Biosystems). Rpl19 gene expression was used for internal nor-
malization. The primer sequences used in this study are listed
in Table S1.
Adenovirus and AAV
Adenovirus expressing scramble shRNA or shRNA targeting
Ppp2ca was purchased from Vector Biolabs (shADV-269223).
The targeting sequence for Ppp2ca is CGACGAGTGTTTAA-
GGAAATA,whichhas beenpreviously reported (47). Themice
were injected by tail vein with 1–2  109 plaque-forming unit
adenovirus/mouse. AAV serotype 8 shRNA targeting Sptlc2
was purchased fromVector Biolabs. The targeting sequence for
Sptlc2 is GCTCATACCAAAGAAATACTT. The mice were
injected by tail vein with 4.5 1011 GC/mouse.
Plasma TG and liver TGmeasurement
Plasma TG levels were measured using a serum triglyceride
determination kit (Sigma; TR0100). Liver was cut into 100-mg
pieces, placed in 700 l of a 3:5 ratio ethanolic KOH and 3 M
KOH and 100% EtOH, and incubated overnight at 55 °C. The
next day, sampleswere vortexedwell andwere spun for 5min at
5,000 rpm at room temperature. 200 l of the supernatant was
transferred and added to 215 l of 1 M MgCl2, vortexed, and
incubated on ice for 10 min. The samples were then spun for 5
min 5,000 rpm at room temperature, and the supernatant was
used to run on a serum triglyceride determination kit (Sigma;
TR0100). The concentration of triglyceride was calculated as
mg/ml and then was converted to mg triglyceride/g liver by
dividing the concentration by 0.069.
Chromatin immunoprecipitation
The protocol for mouse liver ChIP experiment is modified
from our previous reported protocol (48). Liver tissues were
harvested frommaleWTmice treated with or without dexam-
ethasone, minced with a razor blade, and collected in 1 SSC
buffer (150 mM NaCl and 15 mM sodium citrate). The samples
were then washed on a nutator, followed by centrifugation at
4,000 rpm for 3 min at 4 °C to remove supernatant. The liver
pellets were resuspended in PBS and cross-linked with 1%
formaldehyde for 15 min at room temperature with gentle
shaking, and the reaction was quenched with the addition of
125 mM glycine. Centrifugation followed to remove superna-
tant, and the cell pellets were washed with ice-cold PBS plus
protease inhibitor with shaking. Once PBS was removed, the
cells were resuspended in hypotonic buffer (10 mM HEPES at
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2% Nonidet P-40, 1 mM
EDTA, 5% sucrose) with protease inhibitor, 1.5 mM spermine,
and 0.5 mM spermidine added right before use. The cells were
homogenized using a Dounce homogenizer for eight strokes
each sample. Homogenized cells in hypotonic buffer were
mounted onto cushion buffer (10 mM Tris-HCl at pH 7.5, 15
mMNaCl, 60 mM KCl, 1 mM EDTA, 10% sucrose, with protease
inhibitor, 1.5mM spermine, and 0.5mM spermidine added right
before use) and centrifuged at 4,000 rpm at 4 °C for 5 min,
followed by the removal of supernatant. SDS sonication buffer
(50 mM Tris-HCl at pH 8.0, 2 mM EDTA, and 1% SDS added
right before use) was applied to resuspend the nuclei pellet for
sonication at 60% output for five cycles, 10 s each. To remove
insoluble components, the samples were centrifuged at 13,000
rpm for 15min at 4 °C, and the supernatant was collected. Then
1 volume of dilution buffer (20 mM Tris-HCl at pH 8.0, 2 mM
EDTA, 200 mM NaCl, 1% Triton X-100, and 0.1% sodium
deoxycholate) was added to the supernatant and was divided
accordingly for immunoprecipitation overnight (4 g of anti-
bodies: IgG from Santa Cruz Biotechnology (sc-47778), Gene-
Script (A01008), and Srebp1c from Santa Cruz Biotechnology
(sc-1351)). The next day, 30l of 50%proteinA/Gplus-agarose
bead slurry was applied, and the samples were nutated for 2 h at
4 °C. The following 500-l washes were done, all supplemented
with protease inhibitor: oncewith TSE I (20mMTris-HCl at pH
8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, and 0.1%
SDS); oncewithTSE II (20mMTris-HCl at pH8.0, 2mMEDTA,
500 mMNaCl, 1% Triton X-100, and 0.1% SDS); once with TSE
III (10 mM Tris-HCl at pH 8.0, 1 mM EDTA, 0.25 M LiCl, 1%
Nonidet P-40, and 1% sodiumdeoxycholate), and twicewithTE
buffer (10 mM Tris-HCl at pH 8.0 and 1 mM EDTA). Centrifu-
gation at 8,000 rpm at 4 °C for 1 min was used to remove
supernatant between washes. 400 l of freshly prepared elu-
tion buffer (100mMNaHCO3 and 1% SDS) was added to each
sample, and elution buffer (up to 400 l in total) was added
for input. The samples were nutated for 1 h at room temper-
ature. To reverse the cross-linking, after centrifugation,
supernatant was transferred to new Eppendorf tubes, and a
final concentration of 200 mM NaCl was added to each sam-
ple, followed by 65 °C water bath incubation for 	6 h. The
next day, 8 l of 0.5 M EDTA, 16 l of 1 M Tris-HCl at pH 6.5,
and 1.5 l of proteinase K were added to each sample, fol-
lowed by 65 °C water bath incubation for 1 h. To purify DNA,
Qiagen’s PCR purification kit was used (Qiagen), and real-
time qPCR was carried out for data analysis. The primer
sequences used are in Table S1.
Intraperitoneal glucose tolerance test
The mice were fasted for 16 h for the glucose tolerance test.
Themicewere injectedwith glucose (1 g/kg bodyweight) intra-
peritoneally (Sigma; G8270). Blood samples (one drop from tail
vein) were obtained at the 0-, 30-, 60-, 90-, and 120-min time
points to measure glucose levels using CONTOUR blood glu-
cose monitoring system (Contour, Bayer).
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Statistics
The data are expressed as S.D. or S.E. for each group, and
comparisons were analyzed by Student’s t test or analysis of
variance.
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